Safety and efficacy of bendamustine use in patients with chronic lymphocytic leukaemia

被引：0
|
作者：
Lam, J. H. P. [1 ]
Corbett, T. [1 ]
机构：
[1] Brighton & Sussex Univ Hosp NHS Trust, Royal Sussex Cty Hosp, Dept Haematol, Brighton, E Sussex, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2015年 / 169卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
151
引用
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [21] Use of Bendamustine Combined with Rituximab in Chronic Lymphocytic Leukemia Patients: A Single Center Experience
    Ozmen, Deniz
    Keskin, Dilek
    Yurttas, Nurgul Ozgur
    Sadri, Sevil
    Salihoglu, Ayse
    Eskazan, Ahmet Emre
    Ar, M. Cem
    Ongoren, Seniz
    Baslar, Zafer
    Soysal, Teoman
    BLOOD, 2017, 130
  • [22] Bendamustine in Chronic Lymphocytic Leukemia
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (03): : 203 - 205
  • [23] Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study
    Iannitto, Emilio
    Morabito, Fortunato
    Mancuso, Salvatrice
    Gentile, Massimo
    Montanini, Antonella
    Augello, Accursio
    Bongarzoni, Velia
    D'Arco, Alfonso
    Di Renzo, Nicola
    Fazzi, Rita
    Franco, Giovanni
    Marasca, Roberto
    Mule, Antonino
    Musso, Maurizio
    Musto, Pellegrino
    Pennese, Elsa
    Piccin, Andrea
    Rota-Scalabrini, Delia
    Visani, Giuseppe
    Rigacci, Luigi
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (03) : 351 - 357
  • [24] Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia
    Cao, Zhijian
    Ma, Jun
    BLOOD, 2019, 134
  • [25] COST EFFECTIVENESS ANALYSIS OF BENDAMUSTINE AS FIRST LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE NETHERLANDS
    Vandekerckhove, S.
    Holtzer-Goor, K.
    Van Den Steen, D.
    van Megen, Y.
    Huijgens, P.
    Lamotte, M.
    Uyl-de Groot, C.
    VALUE IN HEALTH, 2012, 15 (07) : A425 - A425
  • [26] HTA: EFFICACY AND SAFETY OF THE USE OF RITUXIMAB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
    Souza, K. M.
    Koury, C. D. N.
    Nunes, A. A.
    VALUE IN HEALTH, 2013, 16 (07) : A683 - A683
  • [27] Results from the phase 2 RESONATE™-17 Trial: Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic leukaemia with 17p deletion
    Munir, T.
    O'Brien, S.
    Jones, J. A.
    Coutre, S. E.
    Mato, A. R.
    Hillmen, P.
    Tam, C.
    Osterborg, A.
    Siddiqi, T.
    Thirman, M. J.
    Furman, R. R.
    Ilhan, O.
    Keating, M.
    Call, T. G.
    Brown, J. R.
    Stevens-Brogan, M.
    Li, Y.
    Clow, F.
    James, D.
    Chu, A.
    Hallek, M.
    Stilgenbauer, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 71 - 71
  • [28] Telomeres and prognosis in patients with chronic lymphocytic leukaemia
    Sellmann, Ludger
    de Beer, Dirk
    Bartels, Marius
    Opalka, Bertram
    Nueckel, Holger
    Duehrsen, Ulrich
    Duerig, Jan
    Seifert, Marc
    Siemer, Doerte
    Kueppers, Ralf
    Baerlocher, Gabriela M.
    Roeth, Alexander
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2011, 93 (01) : 74 - 82
  • [29] In defence of the use of modern chemotherapy regimens for the treatment of patients with chronic lymphocytic leukaemia
    Tam, C. S.
    INTERNAL MEDICINE JOURNAL, 2009, 39 (12) : 858 - 859
  • [30] Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia - an updated meta-analysis
    Vidal, Liat
    Gurion, Ronit
    Shargian, Liat
    Dreyling, Martin
    Gafter-Gvili, Anat
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (02) : 234 - 242
12345